Form 4: Cytokinetics EVP Fady Malik Reports Stock Transactions

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, reported the acquisition and disposal of company stock on June 25, 2024.

Summary

• On June 25, 2024, Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, engaged in multiple transactions involving Cytokinetics common stock.
• Malik disposed of 2,000 shares of common stock at a price of $53.74 per share.
• He also exercised options to acquire 5,300 shares at a price of $7.96 per share.
• Subsequently, he disposed of 5,300 shares at a price of $53.71 per share.
• Following these transactions, Malik directly owns 133,004 shares of Cytokinetics common stock.
• Malik also directly owns 63,600 non-qualified stock options.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions. The sentiment is neither positive nor negative as it simply reflects the buying and selling activity of an executive.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the buying and selling activities of company executives. It's a standard practice in publicly traded companies to ensure fair market practices.

Stakeholder Impact

• The transactions may have a minor impact on shareholders as they reflect insider trading activity, which can influence investor sentiment.

Key Dates